INTRODUCTION: HIV incidence is the rate of new infections in a population over time. HIV incidence is a critical indicator needed to assess the status and trends of the HIV epidemic in populations and guide and assess the impact of prevention interventions. METHODS: Several methods exist for estimating population-level HIV incidence: direct observation of HIV incidence through longitudinal follow-up of persons at risk for new HIV infection, indirect measurement of HIV incidence using data on HIV prevalence and mortality in a population, and direct measurement of HIV incidence through use of tests for recent infection (TRIs) that can differentiate "recent" from "non-recent" infections based on biomarkers in cross-sectional specimens. Given the limitations in measuring directly observed incidence and the assumptions needed for indirect measurements of incidence, there is an increasing demand for TRIs for HIV incidence surveillance and program monitoring and evaluation purposes. RESULTS: Over ten years since the introduction of the first TRI, a number of low-, middle-, and high-income countries have integrated this method into their HIV surveillance systems to monitor HIV incidence in the population. However, the accuracy of these assays for measuring HIV incidence has been unsatisfactory to date, mainly due to misclassification of chronic infections as recent infection on the assay. To improve the accuracy of TRIs for measuring incidence, countries are recommended to apply case-based adjustments, formula-based adjustments using local correction factors, or laboratory-based adjustment to minimize error related to assay misclassification. Multiple tests may be used in a recent infection testing algorithm (RITA) to obtain more accurate HIV incidence estimates. CONCLUSION: There continues to be a high demand for improved TRIs and RITAs to monitor HIV incidence, determine prevention priorities, and assess impact of interventions. Current TRIs have noted limitations, but with appropriate adjustments, interpreted in parallel with other epidemiologic data, may still provide useful information on new infections in a population. New TRIs and RITAs with improved accuracy and performance are needed and development of these tools should be supported.
INTRODUCTION:HIV incidence is the rate of new infections in a population over time. HIV incidence is a critical indicator needed to assess the status and trends of the HIV epidemic in populations and guide and assess the impact of prevention interventions. METHODS: Several methods exist for estimating population-level HIV incidence: direct observation of HIV incidence through longitudinal follow-up of persons at risk for new HIV infection, indirect measurement of HIV incidence using data on HIV prevalence and mortality in a population, and direct measurement of HIV incidence through use of tests for recent infection (TRIs) that can differentiate "recent" from "non-recent" infections based on biomarkers in cross-sectional specimens. Given the limitations in measuring directly observed incidence and the assumptions needed for indirect measurements of incidence, there is an increasing demand for TRIs for HIV incidence surveillance and program monitoring and evaluation purposes. RESULTS: Over ten years since the introduction of the first TRI, a number of low-, middle-, and high-income countries have integrated this method into their HIV surveillance systems to monitor HIV incidence in the population. However, the accuracy of these assays for measuring HIV incidence has been unsatisfactory to date, mainly due to misclassification of chronic infections as recent infection on the assay. To improve the accuracy of TRIs for measuring incidence, countries are recommended to apply case-based adjustments, formula-based adjustments using local correction factors, or laboratory-based adjustment to minimize error related to assay misclassification. Multiple tests may be used in a recent infection testing algorithm (RITA) to obtain more accurate HIV incidence estimates. CONCLUSION: There continues to be a high demand for improved TRIs and RITAs to monitor HIV incidence, determine prevention priorities, and assess impact of interventions. Current TRIs have noted limitations, but with appropriate adjustments, interpreted in parallel with other epidemiologic data, may still provide useful information on new infections in a population. New TRIs and RITAs with improved accuracy and performance are needed and development of these tools should be supported.
Authors: Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: A Chawla; G Murphy; C Donnelly; C L Booth; M Johnson; J V Parry; A Phillips; A M Geretti Journal: J Clin Microbiol Date: 2006-12-06 Impact factor: 5.948
Authors: A Romero; V González; M Granell; L Matas; A Esteve; E Martró; I Rodrigo; T Pumarola; J M Miró; A Casanova; E Ferrer; C Tural; J del Romero; C Rodríguez; E Caballero; E Ribera; J Casabona Journal: Sex Transm Infect Date: 2008-11-05 Impact factor: 3.519
Authors: H Irene Hall; Ruiguang Song; Philip Rhodes; Joseph Prejean; Qian An; Lisa M Lee; John Karon; Ron Brookmeyer; Edward H Kaplan; Matthew T McKenna; Robert S Janssen Journal: JAMA Date: 2008-08-06 Impact factor: 56.272
Authors: Carrie L Young; Dale J Hu; Robert Byers; Suphak Vanichseni; Nancy L Young; Robert Nelson; Philip A Mock; Kachit Choopanya; Robert Janssen; Timothy D Mastro; Joanne V Mei Journal: AIDS Res Hum Retroviruses Date: 2003-06 Impact factor: 2.205
Authors: Timothy B Hallett; Basia Zaba; Jim Todd; Ben Lopman; Wambura Mwita; Sam Biraro; Simon Gregson; J Ties Boerma Journal: PLoS Med Date: 2008-04-08 Impact factor: 11.069
Authors: Till Bärnighausen; Claudia Wallrauch; Alex Welte; Thomas A McWalter; Nhlanhla Mbizana; Johannes Viljoen; Natalie Graham; Frank Tanser; Adrian Puren; Marie-Louise Newell Journal: PLoS One Date: 2008-11-04 Impact factor: 3.240
Authors: Li Yu; Oliver Laeyendecker; Sarah K Wendel; Fuxiong Liang; Wei Liu; Xueyan Wang; Lu Wang; Xianwu Pang; Zhongliao Fang Journal: AIDS Res Hum Retroviruses Date: 2015-09-02 Impact factor: 2.205
Authors: Andrew F Longosz; David Serwadda; Fred Nalugoda; Godfrey Kigozi; Veronica Franco; Ronald H Gray; Thomas C Quinn; Susan H Eshleman; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2013-10-25 Impact factor: 2.205
Authors: Neha S Shah; Yen T Duong; Linh-Vi Le; Nguyen Anh Tuan; Bharat S Parekh; Hoang Thi Thanh Ha; Quang Duy Pham; Cao Thi Thu Cuc; Trudy Dobbs; Tran Hong Tram; Truong Thi Xuan Lien; Nick Wagar; Chunfu Yang; Amy Martin; Mitchell Wolfe; Nguyen Tran Hien; Andrea A Kim Journal: AIDS Res Hum Retroviruses Date: 2017-03-13 Impact factor: 2.205
Authors: Katherine E Schlusser; Jacob Konikoff; Allison R Kirkpatrick; Charles Morrison; Tsungai Chipato; Pai-Lien Chen; Marshall Munjoma; Susan H Eshleman; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2017-03-20 Impact factor: 2.205
Authors: Andrew F Longosz; Charles S Morrison; Pai-Lien Chen; Hilmarie H Brand; Eric Arts; Immaculate Nankya; Robert A Salata; Thomas C Quinn; Susan H Eshleman; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2014-11-19 Impact factor: 2.205
Authors: Ethan Klock; George Mwinnya; Leigh Anne Eller; Reinaldo E Fernandez; Hannah Kibuuka; Sorachai Nitayaphan; Josphat Kosgei; Richard D Moore; Merlin Robb; Susan H Eshleman; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2020-05-27 Impact factor: 2.205
Authors: Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong Journal: Clin Microbiol Rev Date: 2018-11-28 Impact factor: 26.132
Authors: Reshma Kassanjee; Christopher D Pilcher; Michael P Busch; Gary Murphy; Shelley N Facente; Sheila M Keating; Elaine Mckinney; Kara Marson; Matthew A Price; Jeffrey N Martin; Susan J Little; Frederick M Hecht; Esper G Kallas; Alex Welte Journal: AIDS Date: 2016-09-24 Impact factor: 4.177